Bringing the First Precision Medicine to Treat CNS Diseases using Innovative Biomarker Discovery Platforms
Time: 4:30 pm
day: Day Three PM
Details:
- Investigating the challenges of identifying and validating pharmacogenomic biomarkers for CNS drugs, such as placebo effects, model gaps, and diagnostic heterogeneity
- Leveraging a novel biomarker, DGM4, discovered through genome-wide screening of blood samples from a prior failed clinical study with liafensine, to predict treatment efficacy in TRD patients
- Launching a global phase 2b study utilizing the DGM4 biomarker to enrich potential responders to liafensine, achieving significant success and paving the way for precision medicine in CNS disorders
